MRNA-1283
MRNA-1283 is a vaccine candidate developed by Moderna, a biotechnology company based in the United States. It is designed to protect against the SARS-CoV-2 virus, which causes COVID-19. The vaccine is based on mRNA technology, similar to Moderna's first COVID-19 vaccine, mRNA-1273.
Development[edit | edit source]
Moderna began development of MRNA-1283 in 2021, following the successful authorization and distribution of its first COVID-19 vaccine, mRNA-1273. The new vaccine candidate is designed to be stored at refrigerator temperatures, making it easier to distribute than mRNA-1273, which requires ultra-cold storage.
Mechanism of Action[edit | edit source]
Like other mRNA vaccines, MRNA-1283 works by instructing cells to produce a protein that triggers an immune response. The vaccine contains a small piece of the SARS-CoV-2 virus's mRNA, which cells use as a blueprint to build the virus's spike protein. The immune system then recognizes this protein as foreign and produces antibodies against it. If the person is later exposed to the actual virus, these antibodies can help protect against infection.
Clinical Trials[edit | edit source]
As of 2022, MRNA-1283 is in Phase 1/2 clinical trials. These trials are designed to test the vaccine's safety, dosage, and immune response in humans. The results of these trials will determine whether the vaccine moves on to Phase 3 trials, which test the vaccine's efficacy in a larger population.
Potential Advantages[edit | edit source]
One potential advantage of MRNA-1283 is its storage requirements. Unlike mRNA-1273, which must be stored at ultra-cold temperatures, MRNA-1283 can be stored at refrigerator temperatures. This could make the vaccine easier to distribute, particularly in areas with limited access to ultra-cold storage.
Another potential advantage is that MRNA-1283 may provide protection against multiple variants of the SARS-CoV-2 virus. This is because the vaccine is designed to target the entire spike protein of the virus, rather than just a specific part of it.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
